Gilead pounced to buy cell therapy company ... because of its early lead against rival firms. The pharma company needs to ensure Kite generates major revenues over the long term, which will ...

That turned out to be one of the best pharma M&A deals of all time. But Gilead's hep C franchise peaked some time ago, and the firm needed another blockbuster to boost its prospects. Kite's lead ...

Bullish option flow detected in Gilead (GILD) with 14,401 calls trading, 4x expected, and implied vol increasing over 4 points to 27.50%.

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Gilead Sciences (GILD – Research Report), with a price ...

Learn more about whether Biogen Inc. or Gilead Sciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

With a market cap of $121,1 billion, Gilead Sciences, Inc. (GILD) is a leading biopharmaceutical company specializing in the discovery, development, and commercialization of innovative medicines.

Story Jan. 10 - Shoreline Biosciences: The cell therapy biotech plans to let go of an undisclosed number of employees tied to a project with Gilead Sciences’ Kite Pharma. Story Jan. 9 - IGM ...

A name noticeably absent from the media release sent out by Ole Miss on Monday of the school's 40 mid-year enrollees was that of Auburn portal transfer defensive back Antonio Kite. Kite committed ...

Founded in 1935 by Khwaja Abdul Ahmeid, Cipla operates through two segments: Pharmaceuticals and New Ventures. Cipla Limited specialises in developing medications, primarily treating respiratory ...

Ugandan doctors attend the contacts of a patient who had tested positive, during the launch of the vaccination for the Sudan strain of Ebola virus, with a trial vaccine at the Mulago Guest House ...